BOCA RATON, Fla., Oct. 14, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the ...
Salix announced the completion and outcome of two Phase 3 studies evaluating the efficacy and safety of budesonide foam in the treatment of active mild to moderate ulcerative proctitis (UP) or ...
Salix Pharmaceuticals Announces Statistically Significant Results for Budesonide Foam in the Treatme
Salix Pharmaceuticals Announces Statistically Significant Results for Budesonide Foam in the Treatment of Active Mild to Moderate Ulcerative Proctitis or Ulcerative Proctosigmoiditis in Two Pivotal ...
<0> Salix Pharmaceuticals, Ltd.Adam C. DerbyshireExecutive Vice President and Chief Financial OfficerorG. Michael FreemanAssociate Vice President, Investor Relations and Corporate ...
BEVERLY, Mass., May 16, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the Company has signed a ...
BOCA RATON, Fla., Sept. 28, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma”, “First Wave”, or the “Company ...
Previous Phase 1b clinical data suggest niclosamide delivers favorable efficacy compared to topical corticosteroid in the treatment of ulcerative proctitis and ulcerative proctosigmoiditis BOCA RATON, ...
Preliminary data from prior Phase 1a/2a trial indicated safety of topical formulation of FW-UP and suggested possible favorable efficacy First Proof of Principle for Treatment of Inflammatory Bowel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback